LTR Pharma Limited (ASX:LTP) Advances Multi-Market Strategy with FDA Milestone and Roxus Launch
LTR Pharma (ASX:LTP) achieves FDA approval path for SPONTAN and launches Roxus to accelerate US market entry.
The Hub of Australian Finance News
LTR Pharma (ASX:LTP) achieves FDA approval path for SPONTAN and launches Roxus to accelerate US market entry.
4DMedical Limited (ASX:4DX) announces $6.5m annual cost reductions, supporting ongoing growth and key milestones.
CLINUVEL (ASX:CUV) reports positive preliminary results from its latest stroke treatment study, highlighting high patient improvement rates.
Orthocell Limited (ASX:OCC) achieves first sales of its Striate+ product in the DACH region, marking a significant expansion in its European markets.
KMD Brands Limited (ASX:KMD) reports a slight revenue increase and a significant net loss in its 1H FY25 results, with no interim dividend declared.
MetalsTech Limited (ASX:MTC) raises $3.3 million through strategic investments to advance the Sturec Gold Project Pre-Feasibility Study.
Vulcan Energy (ASX:VUL) is recognised as an EU Strategic Project under the Critical Raw Materials Act, advancing sustainable lithium supply in Europe.
FleetPartners Group (ASX:FPR) reaches $30 million share buy-back target and completes its Accelerate business transformation, enhancing future profitability.
Tuas Limited (ASX:TUA) reports a 34% revenue increase and returns to profitability in its latest interim financial report.
Venus Metals (ASX:VMC) reports positive exploration results and outlines plans for an upcoming drilling program at the Bellchambers Gold Project.